Company ProfilePremium

Sequoia Financial Group Limited

Company Profile Analysis

Ticker: SEQ.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Sequoia Financial Group Limited - Company showcase

Sequoia Financial Group Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Sequoia Financial Group Limited Overview

Sequoia Financial Group is a micro-cap Australian financial-services company that, until October 2026, was best known as the owner of InterPrac Financial Planning, one of the country's larger non-aligned advice licensees. The group's model rested on two divisions. The first, Licensee & Adviser Services, sold licensing, compliance, platform access and salaried advice. The second, Legal & Administration Services, sells legal documents, company structures, SMSF administration and AML tooling to accountants and lawyers. Smaller media, corporate-finance and minority investment holdings sit alongside them. The collapse of the Shield and First Guardian master funds changed the company's position fundamentally. InterPrac-authorised advisers placed client superannuation into those funds, which triggered ASIC civil-penalty proceedings, more than 900 AFCA complaints, a 10-year banning of the former CEO, a going-concern qualification and the forced exit of InterPrac. What remains is a small, capital-light document and services business, a residual wealth franchise and a listed-equity portfolio. Large contingent-liability questions still overhang all of it.


Company's own description

Sequoia's standard ASX boilerplate (repeated in 2026 announcements) describes it as serving the retail and wholesale clients of financial planners, brokers, accounting firms and legal practitioners. It lists six activities:

  • financial services licensing through three separate AFSLs

  • salaried advice

  • corporate advisory and capital-markets expertise

  • establishment of legal structures and documents

  • media

  • SMSF administration

The FY2025 Annual Report presents the group as streamlined around two scalable divisions:

Licensee & Adviser Services (LAS): Serves both the retail and wholesale advice markets through the InterPrac and Sequoia Wealth Management brands.

Legal & Administration Services (L&AS): FY2025 strategic priorities were to expand adviser numbers at InterPrac, grow Sequoia Wealth Management, grow salaried advice, build a profitable media business and drive operating efficiency.

Independent characterisation

Sequoia was a B2B2C services aggregator sitting between product manufacturers (platforms, super funds, fund managers, insurers) and end investors. Most of its revenue was pass-through.

InterPrac's economics: InterPrac collected advice fees and commissions on behalf of authorised representatives (ARs) and retained a licensee margin. This explains why group revenue exceeded A$100m while operating profit (normalised EBITDA) was only A$4–12m a year. LAS generated A$113.2m of A$124.1m group revenue in FY2025, and the bulk of that was gross adviser revenue.

Legal & Administration Services: This was the genuinely higher-margin, capital-light franchise, built around Docscentre-style document automation, company structures (Castle Corporate, Australian Business Structures), SMSF administration and, from 1 July 2026, an AML platform.

Other assets: These include media (Finance News Network / ShareCafe), corporate finance, and minority stakes in Morrison Securities (20%), Euree Asset Management (20%) and a listed holding in Centrepoint Alliance (about 15% before a September 2026 sell-down).

Revenue model mix

Revenue typeDescriptionIndicative weight
Advice / licensee fees and commissions (pass-through)AR advice fees, ongoing fees and insurance commissions collected under InterPrac / Sequoia Wealth AFSLsDominant: LAS was 91% of FY2025 revenue and 90% of FY2026 revenue (company segment data)
Salaried advice feesDirect advice from employed advisersIncluded in LAS; not separately disclosed
Transactional / subscription servicesLegal documents, company and trust establishment, SMSF administration, AML complianceL&AS: A$9.7m in FY2025, A$10.3m in FY2026
Corporate finance feesCapital-raising and advisory feesIncluded in LAS; weaker trading noted in 1H FY2025
Media / advertisingInvestor-relations video and news (FNN / ShareCafe)—
Investment incomeEquity-accounted and listed-equity returnsNon-operating; drove FY2025 EBITDA uplift

Customers and end markets

  • Financial planners and practices (authorised representatives)

  • Accountants and SMSF practitioners

  • Small legal practices and tax agents

  • Retail and wholesale investors (the advice clients)

  • ASX-listed small caps (media and corporate finance)

All revenue is generated in Australia.

Strategy

Stated strategy (paraphrased from company disclosures)

FY2025 Annual Report:

  • Simplify into two scalable divisions.

  • Expand InterPrac and Sequoia Wealth Management adviser numbers.

  • Grow salaried advice and media.

  • Invest in compliance monitoring, data analytics and adviser platforms.

  • Strengthen governance through the independent AFSL Governance Committee.

1H FY2026 (Feb 2026):

  • Progressively rebalance earnings away from reliance on InterPrac toward higher-control, higher-margin activities: salaried advice, corporate finance and L&AS.

  • Run a comprehensive review of the InterPrac model.

FY2026 outlook (Aug 2026):

  • Make finding a path to resolving the InterPrac legal matters the FY2027 priority.

  • Selectively pursue opportunities in other divisions.

  • Once legal matters are resolved, use the diversified businesses to build a broader earnings base.

Initiatives in the last 24 months

InitiativeDateDetail / target
Two-division restructureFY2025About A$1.5m p.a. employment-cost savings
Five non-core exitsJul–Oct 2024Insurance broking ×2, Informed Investor, Corporate Connect Research, plus closures
AFSL Governance CommitteeFY2025Chaired by Danielle Press
AI compliance tooling; adviser removalsFY2025Response to breaches
Licensee Services growth targetsFY2025 presentationMore advisers, higher revenue per adviser and higher EBITDA. Now superseded.
InterPrac comprehensive review → divestmentFeb–Oct 2026Completed 13 Oct 2026 (Bellbird, A$200,000)
AML platformLive 1 Jul 2026Positions L&AS for AML/CTF reform affecting accountants and lawyers
Cash-raising / asset realisationSep 2026Sell-down of Centrepoint stake; going-concern plan cites realising liquid assets
Capital managementOngoingBuyback ends 18 Sep 2026; dividends suspended until circumstances allow

Medium-term targets

  • Earlier aspirations (FY2023) included a A$300m revenue target within five years and a 15% operating-profit return on equity for every division. These are clearly superseded.

  • No current quantitative guidance has been published for FY2027.

  • ESG targets have not been disclosed.

Products & Services

Licensee & Adviser Services

OfferingDescriptionTarget customerStatus (Oct 2026)
InterPrac Financial Planning (AFSL)Non-aligned licensee giving ARs compliance, PI, approved product list, education and platform access; historically close to the NTAA accounting bodySelf-employed planners and accountant-advisersDivested 13 Oct 2026 to Bellbird Australia for A$200,000
Sequoia Wealth Management (AFSL)Licensee proposition aimed at wholesale / higher-net-worth adviceWholesale-oriented advisersRetained; adviser numbers not disclosed
Sequoia Asset Management (AFSL)Third AFSL in the group; investment / product licensingAdvisers and investorsRetained; detail not disclosed
Salaried adviceEmployed advisers, including InterPrac's salaried team that worked with affected Shield / First Guardian clientsRetail clientsStatus post-sale not disclosed
Clique ParaplanningParaplanning services acquired FY2024Advice practicesRetained (assumed; not confirmed)
Corporate finance / capital marketsCapital raising and corporate advisory for small capsASX micro / small capsRetained; weaker trading in 1H FY2025
Media: Finance News Network, ShareCafeInvestor-relations video, interviews and financial news; rebranding flagged after earlier court proceedingsListed companies, retail investorsRetained
Libertas Financial PlanningFormer licensee (acquired 2019)—Liquidated 2023; AFSL cancelled 14 Aug 2024
General insurance broking (Sequoia Insurance Brokers, InterPrac General Insurance)General insurance brokingSMEs / clientsSold 1 Jul 2024 to WIB Corporate
Two further insurance-broking subsidiariesUnderperforming broking businesses—Sold in 1H FY2026 at a A$2.1m loss
Informed InvestorInvestor media / contentRetail investorsSold 20 Sep 2024 (Powerhouse Ventures)
Corporate Connect ResearchSponsored equity researchListed small capsSold 31 Oct 2024
Shield / First Guardian (on approved product list)Third-party master-fund options placed by certain ARs—New business ceased (FY2025); at centre of litigation

Legal & Administration Services

OfferingDescriptionTarget customerStatus
Docscentre (legal documents)Online legal-document automation: trusts, SMSF deeds, wills / estate documents, company constitutionsAccountants, planners, lawyersCore growth engine; management cites rising market share
Company and trust establishmentIncorporation and structure registrationAccountants / tax agentsRetained
Castle Corporate / Castle LegalBusiness assets acquired Aug 2023, adding share in documents and corporate servicesAccountants / lawyersIntegrated
Australian Business Structures (ABS)Customer book acquired FY2024–FY2025AccountantsIntegrated
SMSF administrationFund administration and complianceSMSF trustees via accountantsRetained
AML platformNew anti-money-laundering compliance platform, live 1 July 2026, timed for AML/CTF "tranche 2" obligations on accountants and lawyersAccountants, lawyers, real estateLaunched FY2027
AI compliance toolsAI-enabled compliance monitoring deployed within L&AS (FY2025)Internal / clientsImplemented

Investments (non-consolidated)

HoldingStakeNature
Morrison Securities20.0% (30 Jun 2026)Clearing / settlement; 80% sold to New Quantum for A$40.5m (2023)
Euree Asset Management20.0% (30 Jun 2026)Multi-asset fund manager supplying options to advisers
Centrepoint Alliance (ASX: CAF)About 15% (May 2026), then sold down (Sep 2026)Listed licensee competitor; part of the A$14.4m listed equities at 30 Jun 2026

Pricing models were not disclosed for any product line.

Financial Narrative

Important comparability note: FY2022 and FY2023 include Morrison Securities (an equities clearer with high pass-through revenue) and the subsequently divested insurance-broking businesses. FY2024 onward is closer to like-for-like. FY2024 NPAT includes a A$27.1m divestment contribution.

Income statement

Sources and notes:

  • FY2022 revenue is derived from FY2023 revenue of A$131.5m being down 10.7%. FY2022 EBITDA of A$12.4m is from the FY2023 AGM address.

  • FY2023 NPAT is derived from FY2024 NPAT growth of 1,012%.

  • FY2024 data is from the company release of 27 Aug 2024.

  • FY2025 data is from the Appendix 4E. The FY2026 release restates FY2025 operating profit as A$9.8m and NPBT as A$5.8m.

  • FY2026 data is from the 28 Aug 2026 release. The audited NPAT is –A$8,576,002.

  • Gross profit and EBIT are not publicly disclosed in the sources reviewed.

Dividend detail

The FY2026 interim of 1.0c was determined on 23 Feb 2026. It was deferred three times and revoked on 13 Aug 2026, so it was never paid. The FY2023 special was declared in September 2023 after Morrison completion; it is attributed to FY2023 here, consistent with the company's statement that FY2024's 7.0c was up 49%.

Margins and growth

  • Revenue CAGR FY2022–FY2026 is –8.0% (derived). Revenue CAGR FY2024–FY2026 is also –8.0% (derived).

  • Gross margin is not meaningful or disclosed, given the pass-through adviser revenue.

Balance sheet

The following were not publicly disclosed in the sources reviewed:

  • Total assets, equity, goodwill and intangibles, and working capital for all years. Goodwill would be material given the InterPrac, Libertas, Castle and ABS acquisitions, and FY2026 included impairment costs.

  • Total debt for FY2025 and FY2026.

The group described itself as debt-free in FY2024. It held a A$15m ANZ acquisition facility in 2023.

FY2025 cash is described as net cash of A$4.4m. FY2026 cash is reported as A$1.6m without net-debt disclosure.

Cash flow

  • FY2023 operating cash flow is derived from FY2024 OCF being up 69%.

  • Capex, free cash flow and dividends paid were not publicly disclosed in the sources reviewed.

  • Buybacks reduced issued capital by 4.3% in FY2024 and continued through FY2025–FY2026. The buyback formally ends on 18 Sep 2026, and a share-cessation notice was lodged on 9 Mar 2026.

Commentary on trends, inflections and drivers

FY2022 → FY2023 (inflection down).

  • Revenue fell 10.7% and operating profit 55.6% as equity-market volumes contracted.

  • Equity Markets revenue dropped 40% to A$41.7m.

  • Non-recurring PI settlements from 2019-era advice (about A$1.6m) hit Licensee Services.

  • Management responded by monetising Morrison (A$40.5m for 80%), the single most value-accretive transaction of the period.

FY2024 (cosmetic peak).

  • Statutory NPAT of A$24.0m was almost entirely the A$27.1m Morrison divestment contribution.

  • Continuing revenue grew 26% to A$124.6m and operating profit 88% to A$8.7m, helped by adviser recruitment.

  • The second half was disrupted by the board-control contest. Management cited employee and adviser unrest and extra retention costs.

FY2025 (simplification).

  • Five non-core exits cut complexity while revenue held at A$124.1m.

  • EBITDA rose 13.7% to A$9.9m, helped by margin discipline and investment-portfolio gains.

  • Cash fell from A$16.8m to A$4.4m net. The decline reflects dividends (7.0c in FY2024 plus 4.0c in FY2025), buybacks and investments; the precise bridge was not disclosed.

FY2026 (structural break).

  • The Shield / First Guardian fallout drove InterPrac ARs down 63% (294 → 110) and LAS revenue down A$18m.

  • Operating profit more than halved to A$4.4m. The first half had actually improved (+75.9% to A$4.8m), which implies a negative second-half operating result of about –A$0.4m (derived).

  • Statutory loss of A$8.6m came from losses on sale of subsidiaries, impairments and higher legal costs. 1H items included a A$0.9m Libertas settlement and a A$2.1m loss on sale of two broking subsidiaries.

  • Cash fell to A$1.6m. Liquidity now rests heavily on the A$14.4m listed-equity book, part of which (Centrepoint) was sold in September 2026 as a cash-raising measure.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Reporting Divisions by Period

PeriodReporting divisions

FY2023

Four divisions: Licensee Services, Equity Markets (incl. Morrison), Professional Services, Direct (media / investments)

FY2024 (transition)

Four divisions, with Morrison deconsolidated

1H FY2025 onward

Two divisions: Licensee & Adviser Services; Legal & Administration Services (plus corporate / investments)

Post-13 Oct 2026

LAS loses InterPrac. Remaining LAS assets are Sequoia Wealth Management, salaried advice, corporate finance and possibly media. The new segment definitions are not yet published.

Revenue by Segment

SegmentFY2024FY2025FY2026

Licensee & Adviser Services revenue (AUD Mn)

—113.295.2

Legal & Administration Services revenue (AUD Mn)

—9.710.3

Group revenue (AUD Mn)

124.6124.1105.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%) and Revenue by Segment (%)

Segment metricFY2025FY2026

LAS YoY growth (%)

—-15.9

L&AS YoY growth (%)

—6.2

LAS share of group revenue (%)

91.290.3

L&AS share of group revenue (%)

7.89.8

Revenue by Segment (Half-Yearly)

Segment1H FY20241H FY2025

LAS revenue (AUD Mn)

57.955.8

Division (FY2023) Overview

Division (FY2023)Revenue AUD MnOperating profit AUD MnComment

Licensee Services

—3.8

About 6.0 before about A$1.6m non-recurring PI settlements from 2019 advice

Equity Markets

41.7—

Revenue down 40%; operating profit down about A$4m

Professional Services

8.52.4

Revenue up 9.0%

Revenue by Segment — Funds under advice

KPIFY2024FY2025FY2026

Funds under advice (AUD Bn)

12.518.0—

Advisers (InterPrac ARs, start → end of year)

—294110

Licensee network advisers (all AFSLs, FY2025 presentation)

—321—

Practices (FY2025 presentation)

—219—

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (AUD Mn)

147.3131.5124.6124.1105.4

Operating profit / normalised EBITDA (AUD Mn)

12.45.58.79.94.4

Net profit before tax (AUD Mn)

———5.9-8.7

Net profit after tax (AUD Mn)

—2.224.03.2-8.6

EPS basic (A$ cents)

———2.59-6.97

Dividends per share, total (A$ cents)

1.44.77.04.00

Dividend (A$ cents, fully franked)

Dividend (A$ cents, fully franked)FY2022FY2023FY2024FY2025FY2026

Interim

0.50.72.02.00

Final

0.902.52.00

Special

04.02.500

Margin Analysis (%)

RatioFY2022FY2023FY2024FY2025FY2026

Operating (EBITDA) margin (%)

8.44.27.08.04.2

Net margin (%)

—1.719.32.6-8.2

Revenue growth YoY (%)

—-10.7-5.2-0.4-15.1

Balance Sheet

MetricFY2024FY2025FY2026

Cash / net cash (AUD Mn)

16.84.41.6

Listed equity investments (AUD Mn)

—16.014.4

Cash Flow

MetricFY2023FY2024

Operating cash flow (AUD Mn)

2.84.8

Financial Analysis

RatioAssessment

ROE / ROA / ROIC

Not calculable from verified data. FY2026 is negative given the A$8.6m loss.

Current ratio, D/E, interest coverage

Not publicly disclosed in sources reviewed. Historically low leverage; FY2026 debt not disclosed.

Net debt / EBITDA

FY2025: net cash, so the ratio is negative. FY2026: not determinable.

Asset turnover, cash conversion cycle

Not meaningful for a licensee / services model; not disclosed.

Revenue by Region and Revenue by Region (%)

RegionFY2024FY2025FY2026

Australia revenue (AUD Mn)

124.6124.1105.4

Australia share of revenue (%)

100100100

Operating Areas

AreaDirectionReason

Legal & Administration Services

Growing (+6.2% in FY2026)

Docscentre share gains, Castle / ABS acquisitions, AML platform investment

Salaried advice / corporate finance

Management says margins are improving (1H FY2026)

Higher-control model; revenue not separately disclosed

InterPrac licensee revenue

Collapsing (–15.9% LAS; ARs –63%)

Shield / First Guardian, HUB24 cessation of new business, adviser departures, ASIC litigation

Insurance broking, research, Informed Investor

Exited

Non-core divestments in FY2025–FY2026

Share Price & Returns

Reference dateShare price (AUD)Source

Sep 2023 (approx.)

Market cap about A$70m

FNN interview

Aug 2025

Market cap about A$37m

TipRanks

23 Feb 2026

0.260

InvestSMART release price

20 Mar 2026

0.230

InvestSMART

1 May 2026

0.205

InvestSMART

22 Jul 2026

0.110

InvestSMART

13 Aug 2026

0.115 → 0.085

InvestSMART

Mid-Oct 2026

0.065 (market cap about A$7.97m)

Listcorp

Valuation Snapshot

MultipleValueComment

Market cap (AUD Mn)

About 8.0

Price × about 122.6m shares

EV/EBITDA

Negative

Cash A$1.6m plus listed equities A$14.4m (30 Jun 2026) exceed market cap, before contingent liabilities and post-balance-date changes

P/B

Not calculable

—

Analyst Conclusions

Management guidance

  • No quantitative FY2027 guidance has been published.

  • The stated priority is to find a path to resolving the InterPrac-related legal matters while selectively pursuing opportunities in other divisions (FY2026 release).

Consensus

None available.

Bull case

  1. Clean exit. If the Bellbird sale and cross-guarantee revocation withstand ASIC scrutiny, the group is ring-fenced from the A$677m-scale Shield / First Guardian exposure. The remaining businesses (L&AS at A$10.3m revenue and growing, plus Sequoia Wealth, media and corporate finance) then sit on about A$16m of cash and listed equities, against a market cap of about A$8m.

  2. AML-led growth. The AML platform (live 1 Jul 2026) and Docscentre share gains could turn L&AS into a recurring, high-margin regtech business that warrants a software-style multiple.

  3. Activist catalyst. AWAG's about 18% stake and its consolidation intentions, together with a fragmented register, create potential for a control transaction once legal noise subsides.

Bear case

  1. Regulatory look-through. ASIC has already litigated once to protect InterPrac creditors and is closely scrutinising the Bellbird deal. A challenge, a claw-back or claims tied to directors' conduct could put liabilities back on the group, which is already carrying a going-concern qualification.

  2. Cash runway. With A$1.6m cash at 30 June 2026, an FY2026 second-half operating result near breakeven or negative, and continuing legal costs, the listed-equity book may be consumed before the residual businesses scale.

  3. Franchise impairment. The scandal, the former CEO's ban and the Libertas precedent may damage Sequoia Wealth Management, media and L&AS relationships with accountants and platforms. That would erode the "diversified operations" management now relies on.

Catalysts and monitorables (next 12 months)

CatalystTimingWhy it matters
ASIC response to the Bellbird sale / cross-guarantee revocationQ4 CY2026 – 1H CY2027Determines whether the liability ring-fence holds
FY2026 Annual Report / AGM (incl. remuneration votes, director elections)About Nov 2026Board renewal; permanent chair and CEO appointments
1H FY2027 results (pro-forma ex-InterPrac)About Feb 2027First view of the residual group's earnings and cash burn
InterPrac v AFCA judgmentUnknownSets loss-allocation precedent
ASIC v InterPrac case management9 Apr 2027Any findings implicating former group officers
Crole Administrative Review Tribunal review (if sought)UnknownReputational read-through
AML/CTF tranche-2 commencement and platform uptakeCY2026–2027L&AS growth
Further asset realisations (Centrepoint, Morrison, Euree)OngoingLiquidity and possible capital return

Concluding analyst verdict

Sequoia Financial Group in October 2026 is a fundamentally different company from the one that reported a 13.7% EBITDA increase and 4.0 cents of franked dividends only fourteen months earlier.

The collapse of the Shield and First Guardian master funds exposed serious alleged oversight failures at InterPrac, the group's dominant revenue engine. It set off a chain of consequences:

  • ASIC civil-penalty proceedings

  • more than 900 AFCA complaints

  • withdrawal of platform support

  • a 63% fall in authorised representatives

  • a statutory loss of A$8.6 million

  • an auditor's going-concern warning

  • the 10-year banning of the founder-CEO

  • the sale of InterPrac for A$200,000, against an A$12.83 million purchase price in 2017

On a narrow balance-sheet view, the stock looks optically cheap. At about A$8 million of market capitalisation, it trades below the A$14.4 million of listed equities and A$1.6 million of cash held at 30 June 2026. The retained Legal & Administration Services business is growing and now has a timely AML product.

That arithmetic is misleading without a liability overlay. The central uncertainty is whether the Bellbird transaction and the revocation of the cross guarantee will survive regulatory and judicial scrutiny. ASIC has shown it is willing to litigate on exactly this point, and it has said publicly that it is examining the deal closely. Legal costs, possible penalties and residual compensation exposure, together with an interim leadership team and a damaged brand, make the equity a binary, event-driven instrument rather than an investment in an operating franchise.

Verdict: Speculative / Avoid for fundamental investors. The stock is suitable only for special-situations capital that can underwrite legal outcomes. A credible re-rating would require three things: ASIC acceptance of the InterPrac exit, appointment of a permanent and credentialed board and CEO, and evidence from the 1H FY2027 accounts that the residual group can operate at or above cash breakeven without consuming its investment portfolio.


All figures are in A$ for fiscal years ending 30 June unless stated. "Derived" figures are arithmetic from disclosed data.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackground / notes

Alex Fabbri

Interim CEO

22 Jul 2026

Background not disclosed in sources reviewed. Delivered the FY2026 results commentary.

David Hentschke

Interim Chair; Non-Executive Director

Interim chair 22 Jul 2026

—

Floriane Allard

Director (remunerated role)

22 Jul 2026

Annual salary A$211,300 plus super and discretionary bonus, which indicates an executive role

Daryl Stout

Head of Licensee Services

FY2025

Appointed to strengthen licensee governance

Danielle Press

Chair, independent AFSL Governance Committee

FY2025

Former ASIC Commissioner. Board status not confirmed.

Natalie Climo

Company Secretary

—

Boardroom Pty Ltd

Executive Leadership Team

NameFormer roleDatesNotes

Garry Crole

Group CEO and MD; director

Director 18 Nov 2016 – 22 Jul 2026

Resigned 21/22 Jul 2026. Banned by ASIC for 10 years from 4 Sep 2026; ASIC found he was not fit and proper. Remains a substantial shareholder (7.3% per FY2024 AR). Can seek review at the Administrative Review Tribunal.

Michael (Mike) Ryan

Chair

Resigned mid-2026

Date discrepancy: Professional Planner reports 27 May 2026; Financial Standard reports 16 Jun 2026

Charles Sweeney

Chair (newly appointed in 2024)

—

Chair during the 2024 control contest

Kevin Pattison

Non-Executive Director

2024 status

—

John Larsen

Non-Executive Director (formerly co-signed results as chair)

About 2019 – May 2024

Stepped down in May 2024

Lizzie Tan

CFO and COO

FY2024

—

Scott Beeton

MD / CEO

About 2017

Led the InterPrac acquisition

Brent Jones

Head of Professional Services; former InterPrac director

—

Nominated by requisitioning shareholders in 2024

Major Shareholders

HolderStakeDate / source

The Australian Wealth Advisors Group (AWAG)

About 18.0–18.2% (22.37m shares)

30 Jan 2025 substantial-holder notice

Unrandom Pty Ltd (Brent Jones-linked)

7.8% (about 10m shares)

FY2024 Annual Report top 20

Garry Crole (and associates)

7.3% (about 9.2m shares)

FY2024 Annual Report. Confirmed as still a substantial shareholder in Jul 2026; director's interest notices lodged 22 and 24 Jul 2026.

A. Jones Group / Glennon Capital

Combined voting power with Unrandom rose from about 22.2% to 27.84% in 2024

Subject to Takeovers Panel orders, Jul 2024

Competitive Landscape

Competitors by Segment

SegmentCompetitorPositioning vs Sequoia

Licensee services

Centrepoint Alliance (ASX: CAF)

500+ ARs plus about 200 self-licensed practices (2025); 1H FY2026 net revenue A$21.5m (+7%). Now a consolidator.

Licensee services

Count Ltd (ASX: CUP)

—

Licensee services

WT Financial Group (ASX: WTL)

Listed licensee in multi-year growth / transformation

Licensee services

The Australian Wealth Advisors Group (ASX: WAG)

Equity-partnership model; about 18% holder of SEQ and 17.1% voting power in CAF

Licensee services

Insignia Financial (advice), AMP (advice)

Institutional-legacy networks

Licensee services

Infocus, Fitzpatricks, Lifespan (private)

Mid-tier non-aligned licensees

Legal documents

NowInfinity (HUB24 / Class), Cleardocs (Thomson Reuters), Legal Consolidated

Direct competitors to Docscentre in trust, SMSF and company documents

SMSF administration

Class, SuperConcepts, Heffron

Larger-scale administrators

Financial media

Market Index, Livewire, Stockhead, Proactive

Compete with FNN / ShareCafe for small-cap IR budgets

Peer Comparison FY2026

MetricSequoia (FY2026)Centrepoint Alliance

Revenue (AUD Mn)

105.4 (gross)

21.5 (net revenue, 1H FY2026 only)

Growth (%)

-15.1

7 (1H FY2026)

Operating margin (%)

4.2—

Company Snapshot

$68M

Revenue

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • Growing L&AS franchise. Revenue rose from A$9.7m to A$10.3m (+6.2%) in FY2026 despite group turmoil (FY2026 release).
  • Liquid investment book. It held A$14.4m in listed equities at 30 June 2026, exceeding the market cap of about A$8m (FY2026 release; Listcorp).
  • Minority stakes with option value. It holds 20% of Morrison Securities and 20% of Euree Asset Management (FY2026 release).
  • Contained InterPrac exposure. The InterPrac sale completed and the cross guarantee was revoked for InterPrac, which on its face caps group exposure (ASX, 13 Oct 2026).
  • Ability to monetise assets. The 80% Morrison sale raised A$40.5m in 2023, showing management can extract value from businesses.
  • New regulated product. The AML platform went live on 1 July 2026, aligned with new compliance demand.
  • Margin improvement in retained businesses. 1H FY2026 operating profit rose 75.9%, credited to salaried advice, corporate finance and L&AS.

Weaknesses

  • Collapse of the core revenue base. InterPrac ARs fell from 294 to 110 in FY2026, and LAS revenue fell A$18.0m.
  • Statutory losses and going-concern doubt. FY2026 NPAT was –A$8.58m, and William Buck flagged a material going-concern uncertainty.
  • Thin cash. Cash fell to A$1.6m at 30 June 2026 from A$4.4m.
  • Leadership vacuum. The CEO and chair are both interim, after the founder-CEO resigned and the chair departed (Jul 2026).
  • Regulatory findings against former leadership. ASIC found Crole not fit and proper and banned him for 10 years from 4 Sep 2026.
  • Pattern of subsidiary exits viewed as liability avoidance. Examples are Libertas (CSLR-funded AFCA determination; AFSL cancelled 2024), the attempted cross-guarantee revocation (Sep 2025), and InterPrac.
  • No shareholder returns. Dividends were suspended and the FY2026 interim was revoked.

Opportunities

  • AML/CTF tranche-2 reform. The reform creates new recurring demand from accountants and lawyers (AML platform launch).
  • Docscentre share gains. Further gains could come through Castle / ABS integration.
  • Simpler, cheaper group. Post-InterPrac, shared costs can fall further; the precedent is about A$1.5m p.a. of savings in FY2025.
  • Recycling listed equities. These can be redeployed into debt-free operations or capital returns once legal matters settle.
  • Corporate activity. The register includes AWAG (about 18%), a strategic investor that has spoken of consolidation.
  • Positive AFCA ruling. A win for InterPrac in its challenge could set a precedent for loss allocation, although InterPrac is now outside the group.

Threats

  • ASIC challenge to the Bellbird sale or cross-guarantee revocation. ASIC is closely scrutinising the deal, and its earlier receiver application targeted exactly this risk.
  • Pre-sale liabilities. Liabilities, legal costs or penalties attributable to the period before the sale could remain with the group (FY2026 Note 2).
  • Further ASIC action. ASIC could act against the group or other officers. The civil case against InterPrac has case management on 9 April 2027.
  • Class actions. Class actions over Shield / First Guardian are being discussed (Professional Planner, Sep 2026).
  • Reputational contagion. Damage could spread to Sequoia Wealth Management and the media brands.
  • Industry levies and insurance. CSLR levy reform and PI market conditions are adverse to small licensees.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
May 2025InterPrac ceases Ferras Merhi's authorisationStart of public Shield / First Guardian exposure
28 Aug 2025FY2025 results: revenue A$124.1m, EBITDA +13.7% to A$9.9m, 4.0c dividends, A$18bn FUA, 321 advisers / 219 practicesHigh-water mark before the crisis
28 Aug 2025AFSL Governance Committee chaired by Danielle Press; Daryl Stout appointed Head of Licensee Services; new Shield / First Guardian business ceasedGovernance response
Sep 2025Sequoia urges trustees to use Operational Risk Financial Requirement reserves for remediationLiability-shifting stance
12 Sep 2025Revocation deed executed to release three subsidiaries from the cross guarantee (disclosed Feb 2026)Later reversed under ASIC pressure
Oct 2025Allegations that advisers were being moved out of InterPrac to avoid liabilities; Sequoia rejects them as unfoundedReputational damage
Oct 2025AFCA raises conflict-of-interest concerns over InterPrac directing complainantsRegulatory friction
13 Nov 2025ASIC civil-penalty proceedings against InterPrac (6,843 clients, about A$677m)Core legal exposure
Nov 2025ASX queries Sequoia over disclosure timing of the ASIC suitContinuous-disclosure scrutiny
Dec 2025Sequoia flags expected PI excess payouts in FY2026Cash drain
24 Dec 2025AFCA lead determination against InterPracSets precedent for about 900+ complaints
Feb 2026Second AFCA lead determination finds Shield PDS warnings were ignoredStrengthens claimant position
23 Feb 20261H FY2026: revenue A$63.4m (+4.6%), operating profit A$4.8m (+75.9%), net loss A$0.25m; interim 1.0c; InterPrac reviewLast "normal" result
2 Mar 2026Cross-guarantee revocation withdrawn after ASIC interventionRegulator signals creditor-protection focus
9–10 Mar 2026InterPrac sues AFCA in Federal CourtPauses determinations
17 Mar 2026Sequoia announces it is exploring options for InterPracExit begins
19 Mar 2026HUB24 to stop accepting new InterPrac business from 31 Mar 2026Commercial death-blow to the licensee
20–23 Mar 2026Trading halt; InterPrac sale to Conquest for A$50,000; about A$11m write-off citedValue destruction crystallised
27 Mar 2026Interim dividend payment delayedCapital preservation
8 Apr 2026ASIC applies for a receiver over cross-guarantee property; ASX compliance letter; pause in tradingEscalation
10 Apr 2026Sequoia calls ASIC's concern unfoundedAdversarial posture
1 May 2026Conquest SSA terminated (conditions unmet)Sale fails
7 May 2026InterPrac names First Guardian investor Melinda Kee as defendant in the AFCA challenge; ASX price query responseReputational damage
May 2026AFCA says it will issue no further InterPrac determinations until the court case ends; complaints exceed 1,000 (ifa)Liability deferred, not removed
13 May / 1 Jun / 26 Jun 2026Dividend payment repeatedly deferred (to 29 Jun, then 26 Aug)ASIC-linked
27 May or 16 Jun 2026Chair Mike Ryan resignsGovernance vacuum
17 Jul 2026Crole ceases as InterPrac responsible manager—
22 Jul 2026Crole resigns; Hentschke interim chair; Fabbri interim CEO; Allard appointedLeadership reset
30–31 Jul 2026ASIC discontinues receiver case after undertakings on the cross guaranteePartial truce
13 Aug 2026Interim dividend revokedNo FY2026 dividends
26 Aug 2026Independent adviser appointed to sell InterPracSecond exit attempt
28 Aug 2026FY2026: revenue A$105.4m (–15%), operating profit A$4.4m, NPAT –A$8.6m; going-concern material uncertainty (William Buck)Solvency question
~1 Sep 2026Centrepoint stake sold down as cash raising takes shapeLiquidity management
4/8 Sep 2026ASIC bans Crole for 10 yearsRegulatory finding against former leadership
18 Sep 2026Buyback formally ends—
13 Oct 2026InterPrac sold to Bellbird for A$200,000; cross guarantee revoked for InterPracTransformational exit
14 Oct 2026ASIC says it is closely scrutinising the transactionKey overhang

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Revenue by Segment (AUD Mn) (FY2024–FY2026): Licensee & Adviser Services revenue fell from AUD 113.2 Mn in FY2025 to AUD 95.2 Mn in FY2026.
Sequoia Financial Group Limited — Revenue by Segment (AUD Mn) (FY2024–FY2026)
Series (AUD Mn)FY2024FY2025FY2026
Licensee & Adviser Services revenue—113.295.2
Legal & Administration Services revenue—9.710.3
Group revenue124.6124.1105.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.